Close

Anavex Life Sciences (AVXL) Phase 2a Alzheimer Study of ANAVEX 2-73 Met Primary and Secondary Endpoints

December 8, 2016 7:06 AM EST Send to a Friend
Anavex Life Sciences Corp. (Nasdaq: AVXL) today announced a positive 57-week update from its Phase 2a study in mild-to-moderate Alzheimer’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login